Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil EL&P Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries Edgewise Therapeutics Inc (NQ: EWTX ) 20.56 -0.62 (-2.93%) Streaming Delayed Price Updated: 1:11 PM EDT, Jul 25, 2024 Add to My Watchlist Quote Overview Detailed Quote Charting Historical Prices News All News News Headlines Press Releases Research Quarterly Reports Insider Filings Other Filings All News about Edgewise Therapeutics Inc < Previous 1 2 3 4 5 6 Next > Stock Market News For July 23: Quick Takes On GE Aerospace, Boeing, Biotechs July 23, 2024 What sectors outperformed after Trump won the 2016 election, and which outperformed during his term? Via Investor's Business Daily Topics Government Exposures Political Biogen Has Up To $10 Billion For Acquisitions; Why These Three Names Make Sense July 16, 2024 Biogen has $8 billion to $10 billion in dry powder for acquisitions. Here are three names the company could examine. Via Investor's Business Daily Cytokinetics Reveals More From The Study That Boosted Shares 83% In A Day May 13, 2024 The company is hoping to take on Bristol Myers Squibb's Camzyos, a treatment for obstructive HCM. Via Investor's Business Daily Edgewise Therapeutics to Present at the RBC Capital Markets Global Healthcare Conference on May 15, 2024 May 10, 2024 From Edgewise Therapeutics Via Business Wire Edgewise Therapeutics: Q4 Earnings Insights February 22, 2024 Via Benzinga How Is The Market Feeling About Edgewise Therapeutics? January 31, 2024 Via Benzinga EWTX Stock Earnings: Edgewise Therapeutics Beats EPS for Q1 2024 May 09, 2024 EWTX stock results show that Edgewise Therapeutics beat analyst estimates for earnings per share the first quarter of 2024. Via InvestorPlace Top 5 Health Care Stocks That Could Sink Your Portfolio In Q2 May 09, 2024 Via Benzinga Edgewise Therapeutics Reports First Quarter 2024 Financial Results and Recent Business Highlights May 09, 2024 From Edgewise Therapeutics Via Business Wire Edgewise Therapeutics Appoints Arlene Morris to its Board of Directors May 07, 2024 From Edgewise Therapeutics Via Business Wire Edgewise Therapeutics Doses First Patient in Phase 2 CIRRUS-HCM Trial of EDG-7500 in Obstructive Hypertrophic Cardiomyopathy (HCM) May 06, 2024 From Edgewise Therapeutics Via Business Wire Edgewise Receives European Medicines Agency (EMA) Orphan Drug Designations for Sevasemten (EDG-5506) for the Treatment of Becker and Duchenne Muscular Dystrophies April 23, 2024 From Edgewise Therapeutics Via Business Wire Edgewise Therapeutics Announces Positive Two-Year Topline Results from the ARCH Open Label Trial of Sevasemten (EDG-5506) in Adults with Becker Muscular Dystrophy (Becker) April 15, 2024 From Edgewise Therapeutics Via Business Wire Edgewise Therapeutics Announces Upcoming Podium Presentation at the American College of Cardiology's 2024 Annual Scientific Session March 28, 2024 From Edgewise Therapeutics Via Business Wire Edgewise Therapeutics to Present at the Cantor Virtual Muscular Dystrophy Symposium on April 2, 2024 March 27, 2024 From Edgewise Therapeutics Via Business Wire Edgewise Therapeutics to Present at the Leerink Partners Global Biopharma Conference on March 11, 2024 March 05, 2024 From Edgewise Therapeutics Via Business Wire Edgewise Therapeutics to Present on EDG-5506 for the Treatment of Becker Muscular Dystrophy at the 2024 MDA Clinical and Scientific Conference February 28, 2024 From Edgewise Therapeutics Via Business Wire Edgewise Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Business Highlights February 22, 2024 From Edgewise Therapeutics Via Business Wire Edgewise Receives U.S. FDA Fast Track Designation for EDG-5506 for the Treatment of Duchenne Muscular Dystrophy (Duchenne) February 13, 2024 From Edgewise Therapeutics Via Business Wire Insider Favorites: 7 Stocks with Bullish Buying Signals February 11, 2024 Although you’ll still want to conduct your due diligence, following the smart money into these insider favorite stocks is tempting. Via InvestorPlace Insiders Buying Edgewise Therapeutics And 2 Other Stocks January 26, 2024 Although U.S. stocks closed higher on Thursday, there were a few notable insider trades. Via Benzinga Why TransCode Therapeutics Shares Are Trading Lower By Over 24%? Here Are Other Stocks Moving In Friday's Mid-Day Session January 19, 2024 Shares of TransCode Therapeutics, Inc. (NASDAQ: RNAZ) fell sharply during Friday’s session. TransCode Therapeutics priced a 5,942,623 share common stock offering at $1.22 per share. TransCode... Via Benzinga 12 Health Care Stocks Moving In Friday's Intraday Session January 19, 2024 Via Benzinga What's Going On With Edgewise Therapeutics Stock? January 19, 2024 Edgewise Therapeutics, Inc. (NASDAQ:EWTX) shares are trading higher Friday after the company announced the pricing of its $240 million underwritten offering of 21,818,182 shares at $11 per share. Via Benzinga World Acceptance Posts Upbeat Earnings, Joins Kaman, Spirit Airlines And Other Big Stocks Moving Higher On Friday January 19, 2024 U.S. stocks traded higher, with the Dow Jones index gaining around 50 points on Friday. Shares of World Acceptance Corporation (NASDAQ: WRLD) rose sharply during Friday’s session following upbeat... Via Benzinga Topics Stocks Exposures US Equities Edgewise Therapeutics Announces Pricing of $240 Million Underwritten Offering of Common Stock January 19, 2024 From Edgewise Therapeutics Via Business Wire 3 Incredible Growth Stocks That Could Soar in 2024, According to Wall Street January 16, 2024 Analysts have high hopes for these three innovation companies in 2024. Via The Motley Fool 12 Health Care Stocks Moving In Thursday's Intraday Session January 11, 2024 Via Benzinga Edgewise Therapeutics Highlights 2023 Accomplishments and Anticipated Milestones for 2024 at the 42nd Annual J.P. Morgan Healthcare Conference January 09, 2024 From Edgewise Therapeutics Via Business Wire 12 Health Care Stocks Moving In Wednesday's After-Market Session December 27, 2023 Via Benzinga < Previous 1 2 3 4 5 6 Next > Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.